drugset / Trial / NCT00403754

Dose Ranging Study for Indacaterol in Japanese Asthma Patients

NCT00403754

Phase 2 Completed 41 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study was designed to provide data about the safety and efficacy of 3 doses of indacaterol (150, 300, and 600 µg) in Japanese asthma patients so that an optimal dose, or doses, could be chosen for testing in later studies.

Timeline

Start
2006-11
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Indacaterol Other / unclassified 300 ug Inhaled
Subject Indacaterol Other / unclassified 600 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications